'Bacteraemia with an MBL-producing Klebsiella pneumoniae: treatment and the potential role of cefiderocol heteroresistance'-authors' response

J Antimicrob Chemother. 2022 Oct 28;77(11):3212. doi: 10.1093/jac/dkac330.

Authors

Lucy S Witt^{1

2}, Eileen M Burd^{1

3

4}, Tugba Ozturk⁴, Sarah W Satola^{1

2

3

4}, David S Weiss^{1

2

4}, Jesse T Jacob^{1

2

4}

Affiliations

¹ Department of Medicine, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA 30322, USA.
² Georgia Emerging Infections Program, Georgia Department of Public Health, Atlanta, GA 30303, USA.
³ Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA.
⁴ Emory School of Medicine, Emory Antibiotic Resistance Center, Atlanta, GA 30322, USA.

PMID: 36177772
DOI: 10.1093/jac/dkac330

No abstract available

Publication types

Editorial
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Comment

MeSH terms

Bacteremia*
Cefiderocol
Cephalosporins / pharmacology
Cephalosporins / therapeutic use
Humans
Klebsiella Infections* / drug therapy
Klebsiella pneumoniae

Substances

Cephalosporins

Grants and funding